Cancer Treatment Reviews
Volume 36, Issue 1 , Pages 83-90 , February 2010

EORTC Elderly Task Force experts’ opinion for the treatment of colon cancer in older patients

  • A.G. Pallis

      Affiliations

    • EORTC Headquarters, EORTC-Elderly Task Force, Avenue E. Mounierlaan, 83/11, B-1200 Brussels, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32 (0)2 774 10 62.
    • ,
  • D. Papamichael

      Affiliations

    • Dpt. of Medical Oncology, B.O.C. Oncology Center, Nicosia, Cyprus
    • ,
  • R. Audisio

      Affiliations

    • University of Liverpool, St. Helens Hospital, Marshalls Cross Road, St. Helens WA9 3DA, UK
    • ,
  • M. Peeters

      Affiliations

    • Dpt. of HepatoGastroenterology, Digestive Oncology Unit, University Hospital Gent, Ghent, Belgium
    • ,
  • G. Folprecht

      Affiliations

    • University Hospital Carl Gustav Carus, Medical Dept. I, Fetscherstr. 74, 01307 Dresden, Germany
    • ,
  • D. Lacombe

      Affiliations

    • EORTC Headquarters, EORTC-Elderly Task Force, Avenue E. Mounierlaan, 83/11, B-1200 Brussels, Belgium
    • ,
  • E. Van Cutsem

      Affiliations

    • Digestive Oncology Unit, University Hospital Gasthuisberg, 3000 Leuven, Belgium

Received 18 September 2009 ,Revised 28 October 2009 ,Accepted 29 October 2009.

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108
  2. Kohne CH, Folprecht G, Goldberg RM, Mitry E, Rougier P. Chemotherapy in elderly patients with colorectal cancer. Oncologist. 2008;13(4):390–402
  3. Balducci L. Geriatric oncology: challenges for the new century. Eur J Cancer. 2000;36(14):1741–1754
  4. Bottomley A, Vanvoorden V, Flechtner H, Therasse P. The challenges and achievements involved in implementing quality of life research in cancer clinical trials. Eur J Cancer. 2003;39(3):275–285
  5. Yellen SB, Cella DF, Leslie WT. Age and clinical decision making in oncology patients. J Natl Cancer Inst. 1994;86(23):1766–1770
  6. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000;5(3):224–237
  7. Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. New Engl J Med. 1999;341(27):2061–2067
  8. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003;21(7):1383–1389
  9. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002;20(5):1192–1202
  10. Balducci L. The geriatric cancer patient: equal benefit from equal treatment. Cancer Control. 2001;8(2 Suppl.):1–25
  11. Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol. 2005;23(13):3112–3124
  12. Townsley CA, Chan KK, Pond GR, Marquez C, Siu LL, Straus SE. Understanding the attitudes of the elderly towards enrolment into cancer clinical trials. BMC Cancer. 2006;6:34
  13. Basche M, Baron A, Eckhardt SG, et al. Barriers to enrollment of elderly adults in early-phase cancer clinical trials. J Oncol Pract. 2008;4(4):162–168
  14. Surgery for colorectal cancer in elderly patients: a systematic review. Colorectal Cancer Collaborative Group. Lancet 2000;356(9234):968–74.
  15. Tan E, Tilney H, Thompson M, Smith J, Tekkis PP. The United Kingdom National Bowel Cancer Project – epidemiology and surgical risk in the elderly. Eur J Cancer. 2007;43(15):2285–2294
  16. van Leeuwen BL, Pahlman L, Gunnarsson U, Sjovall A, Martling A. The effect of age and gender on outcome after treatment for colon carcinoma. A population-based study in the Uppsala and Stockholm region. Crit Rev Oncol Hematol. 2008;67(3):229–236
  17. Ong ES, Alassas M, Dunn KB, Rajput A. Colorectal cancer surgery in the elderly: acceptable morbidity?. Am J Surg. 2008;195(3):344–348
  18. Schiffmann L, Ozcan S, Schwarz F, Lange J, Prall F, Klar E. Colorectal cancer in the elderly: surgical treatment and long-term survival. Int J Colorectal Dis. 2008;23(6):601–610
  19. Gurlich R, Maruna P, Kalvach Z, Peskova M, Cermak J, Frasko R. Colon resection in elderly patients: comparison of data of a single surgical department with collective data from the Czech Republic. Arch Gerontol Geriatr. 2005;41(2):183–190
  20. Chiappa A, Zbar AP, Bertani E, et al. Surgical treatment of advanced colorectal cancer in the elderly. Chir Ital. 2005;57(5):589–596
  21. Makela JT, Kiviniemi H, Laitinen S. Survival after operations for colorectal cancer in patients aged 75 years or over. Eur J Surg. 2000;166(6):473–479
  22. Basili G, Lorenzetti L, Biondi G, et al. Colorectal cancer in the elderly. Is there a role for safe and curative surgery?. ANZ J Surg. 2008;78(6):466–470
  23. Takeuchi K, Tsuzuki Y, Ando T, et al. Should patients over 85 years old be operated on for colorectal cancer?. J Clin Gastroenterol. 2004;38(5):408–413
  24. Louis DJ, Hsu A, Brand MI, Saclarides TJ. Morbidity and mortality in octogenarians and older undergoing major intestinal surgery. Dis Colon Rectum. 2009;52(1):59–63
  25. Gurevitch AJ, Davidovitch B, Kashtan H. Outcome of right colectomy for cancer in octogenarians. J Gastrointest Surg. 2009;13(1):100–104
  26. Lee L, Jannapureddy M, Albo D, et al. Outcomes of Veterans affairs patients older than age 80 after surgical procedures for colon malignancies. Am J Surg. 2007;194(5):646–651
  27. Audisio RA, Zbar AP, Jaklitsch MT. Surgical management of oncogeriatric patients. J Clin Oncol. 2007;25(14):1924–1929
  28. Quaglia A, Capocaccia R, Micheli A, Carrani E, Vercelli M. A wide difference in cancer survival between middle aged and elderly patients in Europe. Int J Cancer. 2007;120(10):2196–2201
  29. Audisio RA, Pope D, Ramesh HS, et al. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol. 2008;65(2):156–163
  30. Slaets JP. Vulnerability in the elderly: frailty. Med Clin North Am. 2006;90(4):593–601
  31. Alves A, Panis Y, Mathieu P, Mantion G, Kwiatkowski F, Slim K. Postoperative mortality and morbidity in French patients undergoing colorectal surgery: results of a prospective multicenter study. Arch Surg. 2005;140(3):278–283[discussion]
  32. Janssen-Heijnen ML, Maas HA, Houterman S, Lemmens VE, Rutten HJ, Coebergh JW. Comorbidity in older surgical cancer patients: influence on patient care and outcome. Eur J Cancer. 2007;43(15):2179–2193
  33. Pope D, Ramesh H, Gennari R, et al. Pre-operative assessment of cancer in the elderly (PACE): a comprehensive assessment of underlying characteristics of elderly cancer patients prior to elective surgery. Surg Oncol. 2006;15(4):189–197
  34. Stocchi L, Nelson H, Young-Fadok TM, Larson DR, Ilstrup DM. Safety and advantages of laparoscopic vs. open colectomy in the elderly: matched-control study. Dis Colon Rectum. 2000;43(3):326–332
  35. Law WL, Chu KW, Tung PH. Laparoscopic colorectal resection: a safe option for elderly patients. J Am Coll Surg. 2002;195(6):768–773
  36. Senagore AJ, Madbouly KM, Fazio VW, Duepree HJ, Brady KM, Delaney CP. Advantages of laparoscopic colectomy in older patients. Arch Surg. 2003;138(3):252–256
  37. Feng B, Zheng MH, Mao ZH, et al. Clinical advantages of laparoscopic colorectal cancer surgery in the elderly. Aging Clin Exp Res. 2006;18(3):191–195
  38. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–318
  39. Zacharias T, Jaeck D, Oussoultzoglou E, Bachellier P, Weber JC. First and repeat resection of colorectal liver metastases in elderly patients. Ann Surg. 2004;240(5):858–865
  40. Mazzoni G, Tocchi A, Miccini M, et al. Surgical treatment of liver metastases from colorectal cancer in elderly patients. Int J Colorectal Dis. 2007;22(1):77–83
  41. Nojiri K, Nagano Y, Tanaka K, et al. Validity of hepatic resection of colorectal liver metastases in the elderly (75 years and older). Anticancer Res. 2009;29(2):583–588
  42. Mann CD, Neal CP, Pattenden CJ, et al. Major resection of hepatic colorectal liver metastases in elderly patients – an aggressive approach is justified. Eur J Surg Oncol. 2008;34(4):428–432
  43. Bockhorn M, Sotiropoulos GC, Sgourakis G, et al. Major liver resections in the elderly – is an aggressive approach justified?. Int J Colorectal Dis. 2009;24(1):83–86
  44. de Liguori-Carino N, van Leeuwen BL, Ghaneh P, Wu A, Audisio RA, Poston GJ. Liver resection for colorectal liver metastases in older patients. Crit Rev Oncol Hematol. 2008;67(3):273–278
  45. Figueras J, Ramos E, Lopez-Ben S, et al. Surgical treatment of liver metastases from colorectal carcinoma in elderly patients. When is it worthwhile?. Clin Transl Oncol. 2007;9(6):392–400
  46. Pallis AG, Mouzas IA. Adjuvant chemotherapy for colon cancer. Anticancer Res. 2006;26(6C):4809–4815
  47. Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med. 2002;136(5):349–357
  48. Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA. 2005;294(21):2703–2711
  49. Neugut AI, Matasar M, Wang X, et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol. 2006;24(15):2368–2375
  50. Bouvier AM, Jooste V, Bonnetain F, et al. Adjuvant treatments do not alter the quality of life in elderly patients with colorectal cancer: a population-based study. Cancer. 2008;113(4):879–886
  51. Fata F, Mirza A, Craig G, et al. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center. Cancer. 2002;94(7):1931–1938
  52. Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol. 1999;17(8):2412–2418
  53. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. New Engl J Med. 2001;345(15):1091–1097
  54. Quasar Collaborative GroupGray R, Barnwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020–2029
  55. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. New Engl J Med. 2005;352(26):2696–2704
  56. Scheithauer W, McKendrick J, Begbie S, et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol. 2003;14(12):1735–1743
  57. Lichtman SM, Wildiers H, Chatelut E, et al. International society of geriatric oncology chemotherapy taskforce: evaluation of chemotherapy in older patients – an analysis of the medical literature. J Clin Oncol. 2007;25(14):1832–1843
  58. Twelves C, Scheithauer W, McKendrick J, et al. Capecitabine versus 5-FU/LV in stage III colon cancer: updated 5-year efficacy data from X-ACT trial and preliminary analysis of relationship between hand-foot syndrome (HFS) and efficacy. In: ASCO gastrointestinal cancers symposium; 2008 [abstr 274].
  59. Field KM, Kosmider S, Desai J, Lim L, Barnett F, Gibbs P. Capecitabine in colorectal cancer: a five-year review of use in routine clinical care. In: ASCO gastrointestinal cancers symposium; 2009.
  60. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006;24(25):4085–4091
  61. McCleary NJ, Meyerhardt J, Green E, et al. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol. 2009;27(15s):[abstr 4010]
  62. Allegra CJ, Yothers G, O’Connell MJ, et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol. 2009;27(20):3385–3390
  63. Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol. 2004;15(9):1330–1338
  64. Chiara S, Nobile MT, Vincenti M, et al. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol. 1998;42(4):336–340
  65. Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002;13(4):566–575
  66. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041–1047
  67. Kohne CH, van CE, Wils J, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol. 2005;23(22):4856–4865
  68. Mitry E, Douillard JY, Van CE, et al. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol. 2004;15(7):1013–1017
  69. Chau I, Norman AR, Cunningham D, et al. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Brit J Cancer. 2004;91(8):1453–1458
  70. Folprecht G, Seymour MT, Saltz L, et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2691 patients in randomized controlled trials. J Clin Oncol. 2008;26(9):1443–1451
  71. Figer A, Perez-Staub N, Carola E, et al. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer. 2007;110(12):2666–2671
  72. Seymour MT, Maughan T, Wasan HS, et al. Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with metastatic colorectal cancer: the FOCUS2 trial. J Clin Oncol. 2007;25;[abstr 9030]
  73. Mitry E, Phelip JM, Bonnetain F, et al. Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients (FFCD 2001-02 trial): results of a planned interim analysis. In; ASCO gastrointestinal cancers symposium; 2008 [abstr 281].
  74. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med. 2004;350(23):2335–2342
  75. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99(16):1232–1239
  76. Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol. 2009;27(2):199–205
  77. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008;26(33):5326–5334
  78. Kozloff M, Sugrue MM, Purdie DM, et al. Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): Results from the BRiTE observational cohort study. J Clin Oncol. 2008;[abstr 4026]
  79. Van CE, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009;[April 30]
  80. Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of bevacizumab and chemotherapy in elderly patients with metastatic colorectal cancer: results from the BEAT observational cohort study. Ann Oncol. 2009;20(Suppl. 7):PD-0005
  81. Bouchahda M, Macarulla T, Spano JP, et al. Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Crit Rev Oncol Hematol. 2008;67(3):255–262

PII: S0305-7372(09)00161-3

doi: 10.1016/j.ctrv.2009.10.008

Cancer Treatment Reviews
Volume 36, Issue 1 , Pages 83-90 , February 2010

Article Tools